Le produit a bien été ajouté au panier.

discount label
H-HAKRRLIF-NH2
Vue en 3D

Biosynth logo

H-HAKRRLIF-NH2

Ref. 3D-PP43163

Taille indéfinieÀ demander
Livraison estimée en/au États-Unis, le mardi 3 décembre 2024

Informations sur le produit

Nom :
H-HAKRRLIF-NH2
Synonymes :
  • NH2-His-Ala-Lys-Arg-Arg-Leu-Ile-Phe-amide
Description :

Peptide H-HAKRRLIF-NH2 is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-HAKRRLIF-NH2 include the following: A novel approach to the design of selective inhibitors for cell cycle cyclin dependent kinases T Perkins - 2013 - search.proquest.comhttps://search.proquest.com/openview/fb15e7ad08e0ad72ac6b1b3c4f5eaa68/1?pq-origsite=gscholar&cbl=18750 Cyclin-dependent kinase 2 inhibitors in cancer therapy: an update S Tadesse , EC Caldon , W Tilley - Journal of medicinal , 2018 - ACS Publicationshttps://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.8b01469 Optimization of non-ATP competitive CDK/cyclin groove inhibitors through REPLACE-mediated fragment assembly S Liu , PN Premnath , JK Bolger, TL Perkins - Journal of medicinal , 2013 - ACS Publicationshttps://pubs.acs.org/doi/abs/10.1021/jm3013882 Structural and functional analysis of cyclin D1 reveals p27 and substrate inhibitor binding requirements S Liu , JK Bolger, LO Kirkland, PN Premnath - ACS chemical , 2010 - ACS Publicationshttps://pubs.acs.org/doi/abs/10.1021/cb1001262 Design of Non-ATP Competitive and Cell Cycle Specific CDK Inhibitors Targeting Cyclin Binding Groove S Liu - 2012 - scholarcommons.sc.eduhttps://scholarcommons.sc.edu/etd/1710/ Peptide Therapeutics: Oncology R Liu, X Li , TC Shih , JS Lee, KS Lam - 2017 - books.rsc.orghttps://books.rsc.org/books/edited-volume/661/chapter/357999 Iterative conversion of cyclin binding groove peptides into druglike CDK inhibitors with antitumor activity PN Premnath , SN Craig, S Liu - Journal of Medicinal , 2015 - ACS Publicationshttps://pubs.acs.org/doi/abs/10.1021/jm5015023 Benzamide capped peptidomimetics as non-ATP competitive inhibitors of CDK2 using the REPLACE strategy PN Premnath , SN Craig, S Liu , C McInnes - Bioorganic & medicinal , 2016 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0960894X16305650 Fragment based discovery of arginine isosteres through REPLACE: Towards non-ATP competitive CDK inhibitors PN Premnath , S Liu , T Perkins, J Abbott - Bioorganic & medicinal , 2014 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0968089613009139 Development of inhibitors of protein-protein interactions through REPLACE: Application to the design and development non-atp competitive cdk inhibitors PN Premnath , S Craig, C McInnes - JoVE (Journal of Visualized , 2015 - jove.comhttps://www.jove.com/t/52441/development-inhibitors-protein-protein-interactions-through-replace Design and Development of a Novel Class of Cell Cycle CDK Inhibitors Targeting the Cyclin Binding Groove Utilizing the Replace Strategy PN Premnath - 2014 - scholarcommons.sc.eduhttps://scholarcommons.sc.edu/etd/2980/ Tumor-targeting peptides: ligands for molecular imaging and therapy N Zhao, Y Qin, H Liu, Z Cheng - Anti-Cancer Agents in , 2018 - ingentaconnect.comhttps://www.ingentaconnect.com/content/ben/acamc/2018/00000018/00000001/art00012 REPLACE: a strategy for iterative design of cyclin-binding groove inhibitors MJI Andrews, G Kontopidis , C McInnes , A Plater - , 2006 - Wiley Online Libraryhttps://chemistry-europe.onlinelibrary.wiley.com/doi/abs/10.1002/cbic.200600189 Cyclin Dependent Kinase Inhibitors as Drug Targets for Cancer-A Review M Krishnaveni - researchgate.nethttps://www.researchgate.net/profile/Marimuthu-Krishnaveni/publication/320322652_Cyclin_Dependent_Kinase_Inhibitors_as_Drug_Targets_for_Cancer-A_Review/links/59de336caca27247d7942624/Cyclin-Dependent-Kinase-Inhibitors-as-Drug-Targets-for-Cancer-A-Review.pdf Targeting Protein-Protein Interactions to Inhibit Cyclin-Dependent Kinases M Klein - Pharmaceuticals, 2023 - mdpi.comhttps://www.mdpi.com/1424-8247/16/4/519 An overview on the prospective CDKs inhibitors as anti-cancer drugs KH Oudah , NS Abdou , RAT Serya - Journal of American , 2017 - researchgate.nethttps://www.researchgate.net/profile/Khulood-Oudah-2/publication/316158160_An_overview_on_the_prospective_CDKs_inhibitors_as_anti-cancer_drugs_Review_article/links/5bcd7d5b458515f7d9d02bdd/An-overview-on-the-prospective-CDKs-inhibitors-as-anti-cancer-drugs-Review-article.pdf Inhibition of the cell cycle with chemical inhibitors: A targeted approach JPI Welburn , JA Endicott - Seminars in cell & developmental biology, 2005 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S1084952105000327 Εκφρalphaση κalphaι alphaποuόΜωση της alphaΜalphaσÏ ΜΎÏ alphaσuέΜης πρωτεΐΜης Cyclin A τοÏ  alphaΜΞρÏŜποÏ  στηΜ Escherichia coli κalphaι χalphaρalphaκτηρισuός της uε πιΞalphaΜούς alphaΜalphaστολείς Î’ ΝικολόποÏ λος - 2014 - ir.lib.uth.grhttps://ir.lib.uth.gr/xmlui/bitstream/handle/11615/44427/12642.pdf?sequence=1 Highly potent p21WAF1-derived peptide inhibitors of CDK-mediated pRb phosphorylation: Delineation and structural insight into their interactions with cyclin A DI Zheleva, C McInnes , AL Gavine - Journal of peptide , 2002 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1034/j.1399-3011.2002.21014.x Peptides or small molecules? Different approaches to develop more effective CDK inhibitors D Cirillo, F Pentimalli , A Giordano - Current medicinal , 2011 - ingentaconnect.comhttps://www.ingentaconnect.com/content/ben/cmc/2011/00000018/00000019/art00005 Cyclin dependent kinase (CDK) inhibitors as anticancer drugs C Sanchez-Martaca­nez, LM Gelbert, MJ Lallena - Bioorganic & medicinal , 2015 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0960894X15005843 Peptidomimetic Design of CDK Inhibitors Targeting theRecruitment Site of the Cyclin Subunit C McInnes , MJ Andrews, DI Zheleva - -Anti-Cancer Agents, 2003 - ingentaconnect.comhttps://www.ingentaconnect.com/content/ben/cmcaca/2003/00000003/00000001/art00007 REPLACE Strategy for Generating Non-ATP-Competitive Inhibitors of Cell Cycle Protein Kinases C McInnes - Protein-Protein Interactions in Drug Discovery, 2013 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/9783527648207.ch12 Efficient soluble expression of active recombinant human cyclin A2 mediated by E. coli molecular chaperones AI Grigoroudis, C McInnes , PN Premnath - Protein expression and , 2015 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S1046592815000698 ATP-noncompetitive CDK inhibitors for cancer therapy: an overview AA Abate, F Pentimalli , L Esposito - Expert opinion on , 2013 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.1517/13543784.2013.798641

Avis:
Nos produits sont destinés uniquement à un usage en laboratoire. Pour tout autre usage, veuillez nous contacter.
Marque:
Biosynth
Stockage à long terme :
Notes :

Propriétés chimiques

MDL:
Point de fusion :
Point d'ébullition :
Point d'éclair :
Densité :
Concentration :
EINECS :
Merck :
Code SH :

Informations sur les risques

Numéro ONU :
EQ:
Classe :
Phrases R :
Phrases S :
Transport aérien interdit :
Informations sur les risques :
Groupe d'emballage :
LQ :

Question d’ordre technique sur : 3D-PP43163 H-HAKRRLIF-NH2

Veuillez plutôt utiliser le panier afin de demander un devis ou passer commande

Si vous souhaitez demander un devis ou passer commande, veuillez plutôt ajouter les produits souhaités à votre panier, puis demander un devis ou passer commande à partir de votre panier. C'est une méthode plus rapide, plus économique, et vous pourrez bénéficier des remises disponibles ainsi que d'autres avantages

* Champ obligatoire
Bienvenue chez CymitQuimica !Nous utilisons des cookies pour améliorer votre visite. Nous n’incluons pas de publicité.

Veuillez consulter notre Politique de Cookies pour plus de détails ou ajustez vos préférences dans "Configurer".